zanamivir has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aires, L; Alisson-Silva, F; Amaral, FC; Antônia, J; Báfica, A; Barroso, SPC; Burgel, PR; Chollet-Martin, S; Costa, VV; Cunha, FQ; de Oliveira Formiga, R; de Souza, FRO; Faria, LF; Fonseca, FR; Heck, N; Hurtado-Nedelec, MM; Lorenzini, CB; Macauley, MS; Mansur, DS; Martin, C; Maurici, R; Mendes, DAGB; Morrot, A; Natale, CC; Paula, NM; Queiroz-Junior, CM; Rocha, EL; Santos, AA; Santos, FRS; Silva, PCS; Sordi, R; Souza, CF; Spiller, F; Starick, MR; Van Weyenbergh, J; Wanderley, CWS; Witko-Sarsat, V | 1 |
| Chan, KKP; Hui, DSC | 1 |
1 review(s) available for zanamivir and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Antiviral therapies for influenza.
Topics: Antiviral Agents; COVID-19; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
1 other study(ies) available for zanamivir and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Neuraminidase is a host-directed approach to regulate neutrophil responses in sepsis and COVID-19.
Topics: Animals; COVID-19; Humans; Lipopolysaccharides; Matrix Metalloproteinase 9; Mice; Neuraminidase; Neutrophils; Oseltamivir; Reactive Oxygen Species; Sepsis; Zanamivir | 2023 |